OBJECTIVE: To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue. METHODS: Individual patient data from placebo-controlled, randomized trials of rosiglitazone (n = 5) or pioglitazone (n = 1) were combined. Generalized estimating equation (GEE) models were used to estimate the treatment effect on changes in limb fat mass. RESULTS: In the combined dataset of 427 patients, the baseline median age was 45 years, 86% were male, 80% were Caucasian, 63% were receiving stavudine (d4T) or zidovudine (AZT), 66% were on protease inhibitors, and median body mass index was 23 kg/m(2). In a univariate GEE model, TZD was associated with an increase in limb fat mass (coeff = 0.14 kg vs placebo, P = .04). In a multivariable GEE model, patients receiving pioglitazone had significantly higher limb fat mass gains (coeff = 0.35 kg, P < or = .01) compared to patients receiving placebo, while patients on rosiglitazone did not (coeff = 0.05 kg, P = .48). Interactions between thymidine analogue use and rosiglitazone and pioglitazone were not significant. CONCLUSIONS: In this meta-analysis, pioglitazone therapy was more effective than placebo to increase limb fat mass whereas rosiglitazone was not significantly better than placebo. The effectiveness of these drugs did not vary according to whether the patients were receiving thymidine analogues.
OBJECTIVE: To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue. METHODS: Individual patient data from placebo-controlled, randomized trials of rosiglitazone (n = 5) or pioglitazone (n = 1) were combined. Generalized estimating equation (GEE) models were used to estimate the treatment effect on changes in limb fat mass. RESULTS: In the combined dataset of 427 patients, the baseline median age was 45 years, 86% were male, 80% were Caucasian, 63% were receiving stavudine (d4T) or zidovudine (AZT), 66% were on protease inhibitors, and median body mass index was 23 kg/m(2). In a univariate GEE model, TZD was associated with an increase in limb fat mass (coeff = 0.14 kg vs placebo, P = .04). In a multivariable GEE model, patients receiving pioglitazone had significantly higher limb fat mass gains (coeff = 0.35 kg, P < or = .01) compared to patients receiving placebo, while patients on rosiglitazone did not (coeff = 0.05 kg, P = .48). Interactions between thymidine analogue use and rosiglitazone and pioglitazone were not significant. CONCLUSIONS: In this meta-analysis, pioglitazone therapy was more effective than placebo to increase limb fat mass whereas rosiglitazone was not significantly better than placebo. The effectiveness of these drugs did not vary according to whether the patients were receiving thymidine analogues.
Authors: Marisa Tungsiripat; Dalia El Bejjani; Nesrine Rizk; Mary Ann O'riordan; Allison C Ross; Corrilynn Hileman; Norma Storer; Danielle Harrill; Grace A McComsey Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: E Arioglu; J Duncan-Morin; N Sebring; K I Rother; N Gottlieb; J Lieberman; D Herion; D E Kleiner; J Reynolds; A Premkumar; A E Sumner; J Hoofnagle; M L Reitman; S I Taylor Journal: Ann Intern Med Date: 2000-08-15 Impact factor: 25.391
Authors: Mina John; Elizabeth J McKinnon; Ian R James; David A Nolan; Susan E Herrmann; Corey B Moore; Alex J White; Simon A Mallal Journal: J Acquir Immune Defic Syndr Date: 2003-05-01 Impact factor: 3.731
Authors: Andrew Carr; Cassy Workman; Don E Smith; Jennifer Hoy; Jeff Hudson; Nicholas Doong; Allison Martin; Janaki Amin; Judith Freund; Matthew Law; David A Cooper Journal: JAMA Date: 2002-07-10 Impact factor: 56.272
Authors: Marie C Gelato; Dennis C Mynarcik; Joyce L Quick; Roy T Steigbigel; Jack Fuhrer; Collin E M Brathwaite; John S Brebbia; Mark R Wax; Margaret A McNurlan Journal: J Acquir Immune Defic Syndr Date: 2002-10-01 Impact factor: 3.731
Authors: Kevin E Yarasheski; W Todd Cade; E Turner Overton; Kristin E Mondy; Sara Hubert; Erin Laciny; Coco Bopp; Sherry Lassa-Claxton; Dominic N Reeds Journal: Am J Physiol Endocrinol Metab Date: 2010-10-19 Impact factor: 4.310
Authors: David E Vance; Pariya L Fazeli; Joan E Dodson; Michelle Ackerman; Michele Talley; Susan J Appel Journal: J Neurosci Nurs Date: 2014-10 Impact factor: 1.230
Authors: Marshall J Glesby; Jeanine Albu; Ya-Lin Chiu; Kirsis Ham; Ellen Engelson; Qing He; Varalakshmi Muthukrishnan; Henry N Ginsberg; Daniel Donovan; Jerry Ernst; Martin Lesser; Donald P Kotler Journal: PLoS One Date: 2013-04-12 Impact factor: 3.240